# PAVmed Inc.: financial statements, quarterly

PAVM · Nasdaq · CIK 1624326 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pavm.md) · [Financials](/companies/pavm/financials.md) · [Filings](/companies/pavm/filings.md) · [Insiders](/companies/pavm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pavm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8](/filings/0001493152-24-045258.md) | [1.0 d](/filings/0001641172-25-000364.md) | [1.0](/filings/0001641172-25-010433.md) | [1.0](/filings/0001493152-25-011923.md) | [1.0](/filings/0001493152-25-022017.md) | [0.0 d](/filings/0001437749-26-010115.md) | [0.0](/filings/0001437749-26-017121.md) | [0.0](/filings/0001437749-26-027733.md) | [0.0](/filings/0001493152-25-022017.md) | [0.1 d](/filings/0001437749-26-010115.md) | [0.0](/filings/0001437749-26-017121.md) | [0.0](/filings/0001437749-26-027733.md) |
| Cost of revenue | $m | [1.8](/filings/0001493152-24-045258.md) | [1.6 d](/filings/0001641172-25-000364.md) | [1.7](/filings/0001641172-25-010433.md) | [1.7](/filings/0001493152-25-011923.md) | [1.4](/filings/0001493152-25-022017.md) | [0.0 d](/filings/0001437749-26-010115.md) | [0.0](/filings/0001437749-26-017121.md) | [0.0](/filings/0001437749-26-027733.md) | [0.1](/filings/0001493152-25-022017.md) | [0.1 d](/filings/0001437749-26-010115.md) | [0.1](/filings/0001437749-26-017121.md) | [0.1](/filings/0001437749-26-027733.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [3.2](/filings/0001493152-24-045258.md) | [3.6 d](/filings/0001641172-25-000364.md) | [1.9](/filings/0001641172-25-010433.md) | [1.6](/filings/0001493152-25-011923.md) | [1.5](/filings/0001493152-25-022017.md) | [0.8 d](/filings/0001437749-26-010115.md) | [0.8](/filings/0001437749-26-017121.md) | [0.8](/filings/0001437749-26-027733.md) | [1.1](/filings/0001493152-25-022017.md) | [1.8 d](/filings/0001437749-26-010115.md) | [1.4](/filings/0001437749-26-017121.md) | [2.1](/filings/0001437749-26-027733.md) |
| Operating income | $m | [(15.5)](/filings/0001493152-24-045258.md) | [(16.4) d](/filings/0001641172-25-000364.md) | [(14.0)](/filings/0001641172-25-010433.md) | [(13.7)](/filings/0001493152-25-011923.md) | [(11.6)](/filings/0001493152-25-022017.md) | [(5.2) d](/filings/0001437749-26-010115.md) | [(5.4)](/filings/0001437749-26-017121.md) | [(4.7)](/filings/0001437749-26-027733.md) | [(4.8)](/filings/0001493152-25-022017.md) | [(6.8) d](/filings/0001437749-26-010115.md) | [(8.0)](/filings/0001437749-26-017121.md) | [(7.0)](/filings/0001437749-26-027733.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001641172-25-010433.md) | [0.0](/filings/0001493152-25-011923.md) | [0.0 d](/filings/0001493152-25-022017.md) | [(0.0) d](/filings/0001437749-26-010115.md) | [0.0](/filings/0001437749-26-017121.md) | [0.0](/filings/0001437749-26-027733.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-017121.md) | [0.0](/filings/0001437749-26-027733.md) | not reported | not reported | [0.0](/filings/0001437749-26-017121.md) | [0.0](/filings/0001437749-26-027733.md) |
| Net income | $m | [(17.7)](/filings/0001493152-24-045258.md) | [(14.0) d](/filings/0001641172-25-000364.md) | [(15.2)](/filings/0001641172-25-010433.md) | [(10.8)](/filings/0001493152-25-011923.md) | [64.4](/filings/0001493152-25-022017.md) | [1.4 d](/filings/0001437749-26-010115.md) | [19.0](/filings/0001437749-26-017121.md) | [(11.9)](/filings/0001437749-26-027733.md) | [(5.4)](/filings/0001493152-25-022017.md) | [(1.3) d](/filings/0001437749-26-010115.md) | [(0.1)](/filings/0001437749-26-017121.md) | [(5.4)](/filings/0001437749-26-027733.md) |
| Diluted EPS | $ per share | [(2.38)](/filings/0001493152-24-045258.md) | not reported | [(2.62)](/filings/0001641172-25-010433.md) | [(1.19)](/filings/0001493152-25-011923.md) | [1.44](/filings/0001493152-25-022017.md) | not reported | [10.10](/filings/0001437749-26-017121.md) | [(22.08)](/filings/0001437749-26-027733.md) | [(0.29)](/filings/0001493152-25-022017.md) | not reported | [(4.42)](/filings/0001437749-26-017121.md) | [(0.87)](/filings/0001437749-26-027733.md) |
| Basic EPS | $ per share | [(2.38)](/filings/0001493152-24-045258.md) | not reported | [(2.62)](/filings/0001641172-25-010433.md) | [(1.19)](/filings/0001493152-25-011923.md) | [6.43](/filings/0001493152-25-022017.md) | not reported | [38.26](/filings/0001437749-26-017121.md) | [(22.08)](/filings/0001437749-26-027733.md) | [(0.29)](/filings/0001493152-25-022017.md) | not reported | [(4.42)](/filings/0001437749-26-017121.md) | [(0.87)](/filings/0001437749-26-027733.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | period not labelled (2025-02-14) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.6](/filings/0001641172-25-000364.md) | [25.5](/filings/0001493152-24-018913.md) | [25.5](/filings/0001493152-24-031268.md) | [0.8](/filings/0001493152-24-045258.md) | [1.2](/filings/0001437749-26-010115.md) | not reported | [2.7](/filings/0001641172-25-010433.md) | [4.0](/filings/0001493152-25-011923.md) | [3.1](/filings/0001493152-25-022017.md) | [1.5](/filings/0001437749-26-027733.md) | [6.5](/filings/0001437749-26-017121.md) | [3.8](/filings/0001437749-26-027733.md) |
| Current assets | $m | [24.5](/filings/0001641172-25-000364.md) | [29.6](/filings/0001493152-24-018913.md) | [30.2](/filings/0001493152-24-031268.md) | [2.1](/filings/0001493152-24-045258.md) | [2.2](/filings/0001437749-26-010115.md) | not reported | [3.6](/filings/0001641172-25-010433.md) | [5.5](/filings/0001493152-25-011923.md) | [4.2](/filings/0001493152-25-022017.md) | [2.6](/filings/0001437749-26-027733.md) | [7.4](/filings/0001437749-26-017121.md) | [4.9](/filings/0001437749-26-027733.md) |
| Total assets | $m | [33.1](/filings/0001641172-25-000364.md) | [37.3](/filings/0001493152-24-018913.md) | [39.4](/filings/0001493152-24-031268.md) | [30.6](/filings/0001493152-24-045258.md) | [30.7](/filings/0001437749-26-010115.md) | not reported | [52.8](/filings/0001641172-25-010433.md) | [43.9](/filings/0001493152-25-011923.md) | [38.1](/filings/0001493152-25-022017.md) | [38.8](/filings/0001437749-26-027733.md) | [45.4](/filings/0001437749-26-017121.md) | [40.2](/filings/0001437749-26-027733.md) |
| Current liabilities | $m | [54.2](/filings/0001641172-25-000364.md) | [55.0](/filings/0001493152-24-018913.md) | [53.4](/filings/0001493152-24-031268.md) | [37.6](/filings/0001493152-24-045258.md) | [35.4](/filings/0001437749-26-010115.md) | not reported | [9.8](/filings/0001641172-25-010433.md) | [10.5](/filings/0001493152-25-011923.md) | [10.5](/filings/0001493152-25-022017.md) | [14.8](/filings/0001437749-26-027733.md) | [3.7](/filings/0001437749-26-017121.md) | [4.1](/filings/0001437749-26-027733.md) |
| Total liabilities | $m | [57.1](/filings/0001641172-25-000364.md) | [57.8](/filings/0001493152-24-018913.md) | [58.1](/filings/0001493152-24-031268.md) | [39.9](/filings/0001493152-24-045258.md) | [37.7](/filings/0001437749-26-010115.md) | not reported | [11.9](/filings/0001641172-25-010433.md) | [12.5](/filings/0001493152-25-011923.md) | [12.3](/filings/0001493152-25-022017.md) | [16.5](/filings/0001437749-26-027733.md) | [20.4](/filings/0001437749-26-017121.md) | [20.9](/filings/0001437749-26-027733.md) |
| Shareholders' equity | $m | [(53.8)](/filings/0001641172-25-000364.md) | [(68.8)](/filings/0001493152-24-018913.md) | [(73.9)](/filings/0001493152-24-031268.md) | [(4.9)](/filings/0001493152-24-045258.md) | [(2.5)](/filings/0001437749-26-010115.md) | [2.5](/filings/0001493152-25-011923.md) | [45.0](/filings/0001641172-25-010433.md) | [37.5](/filings/0001493152-25-011923.md) | [32.5](/filings/0001493152-25-022017.md) | [34.0](/filings/0001437749-26-027733.md) | [39.5](/filings/0001437749-26-017121.md) | [35.0](/filings/0001437749-26-027733.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.1) d](/filings/0001493152-24-045258.md) | [(11.9) d](/filings/0001641172-25-000364.md) | [(13.1)](/filings/0001641172-25-010433.md) | [(11.7) d](/filings/0001493152-25-011923.md) | [(8.9) d](/filings/0001493152-25-022017.md) | [0.1 d](/filings/0001437749-26-010115.md) | [(1.6)](/filings/0001437749-26-017121.md) | [(1.2) d](/filings/0001437749-26-027733.md) | [(0.9) d](/filings/0001493152-25-022017.md) | [(1.6) d](/filings/0001437749-26-010115.md) | [(2.6)](/filings/0001437749-26-017121.md) | [(2.7) d](/filings/0001437749-26-027733.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001493152-24-045258.md) | [0.2 d](/filings/0001641172-25-000364.md) | [0.0](/filings/0001641172-25-010433.md) | [0.0 d](/filings/0001493152-25-011923.md) | [0.0 d](/filings/0001493152-25-022017.md) | [0.0 d](/filings/0001437749-26-010115.md) | [0.0](/filings/0001437749-26-017121.md) | [0.0 d](/filings/0001437749-26-027733.md) | [0.0 d](/filings/0001493152-25-022017.md) | [0.0 d](/filings/0001437749-26-010115.md) | [0.0](/filings/0001437749-26-017121.md) | [0.0 d](/filings/0001437749-26-027733.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [89.8](/filings/0001493152-23-040620.md) | [6.5](/filings/0001493152-24-018913.md) | [7.0](/filings/0001493152-24-031268.md) | [7.5](/filings/0001493152-24-045258.md) | [8.7](/filings/0001641172-25-010433.md) | [9.2](/filings/0001493152-25-011923.md) | [44.5](/filings/0001493152-25-022017.md) | [1.7](/filings/0001437749-26-017121.md) | [0.6](/filings/0001437749-26-027733.md) | [21.6](/filings/0001493152-25-022017.md) | [1.6](/filings/0001437749-26-017121.md) | [6.3](/filings/0001437749-26-027733.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,995,918 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001437749-26-027733.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.